Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From bench to bedside: how dynamic hollow-fibre in vitro infection experiments and mathematical modelling can inform PK/PD targets for teicoplanin.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

Same author

Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations.

The Lancet. Microbe·2026

Same author

Geographical Differences in the Epidemiology and Treatment of Candida Prosthetic Joint Infections.

Open forum infectious diseases·2026

Same author

Bioactive cationic lipidated oligomers (CLOs) as antimicrobial materials: metabolomic insights into MRSA membrane disruption.

Biomaterials science·2026

Same author

A Study of Antibiotic Tolerance to Levofloxacin and Rifampin in <i>Staphylococcus aureus</i> Isolates Causing Prosthetic Joint Infections: Clinical Relevance and Treatment Challenges.

Antibiotics (Basel, Switzerland)·2026

Same author

Genomic profile of extraintestinal pathogenic <i>Escherichia coli</i> isolates from prosthetic joint infections: The search for molecular fingerprints.

Virulence·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

PK/PD models in antibacterial development.

Tony Velkov¹, Phillip J Bergen, Jaime Lora-Tamayo

¹Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, 381 Royal Parade, Parkville, Victoria 3052, Australia.

Current Opinion in Microbiology

|July 23, 2013

Summary

This summary is machine-generated.

Novel antibiotics are crucial for combating bacterial superbugs. In vitro pharmacokinetic/pharmacodynamic (PK/PD) and animal models accelerate antibiotic development, optimizing clinical trials and reducing costs.

More Related Videos

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Related Experiment Videos

Last Updated: May 9, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Area of Science:

Microbiology
Pharmacology
Infectious Diseases

Background:

Antibiotic resistance in bacterial 'superbugs' necessitates the development of novel antimicrobial agents.
Pharmacokinetic/pharmacodynamic (PK/PD) studies are vital for understanding drug efficacy.
Validated in vitro and in vivo models are essential for antibiotic discovery.

Purpose of the Study:

To review key in vitro PK/PD and animal infection models used in antibiotic discovery and development.
To highlight the role of these models in identifying predictive PK/PD indices.
To emphasize their utility in optimizing clinical trial design.

Main Methods:

Review of established in vitro pharmacokinetic/pharmacodynamic (PK/PD) models.
Analysis of validated animal infection models.
Synthesis of data linking PK/PD indices to antimicrobial efficacy.

Main Results:

In vitro PK/PD and animal models are critical tools in antibiotic development.
These models effectively identify predictive PK/PD indices for novel antibiotics.
Results from these models aid in optimizing study designs for clinical trials.

Conclusions:

Validated in vitro PK/PD and animal infection models significantly accelerate antibiotic discovery and development.
These models offer a pathway to minimize the cost and duration of clinical trials.
Continued utilization of these models is expected to yield substantial contributions to combating infectious diseases.